Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Asthma Who Participated in Study DRI16762 or ACT18301

NCT06609239 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06609239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06609239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Asthma Who Participated in Study DRI16762 or ACT18301
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
September 30, 2024
Completion date
January 20, 2031
Enrollment
900 (estimated)
Sites
150

Conditions

As the registry lists them; a condition with its own page is linked.

asthma